<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Burmester, Gerd-Rüdiger</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Adalimumab Therapy is Effective and Well Tolerated in AS, RA, and PsA Patients with a History of Insufficient Response or Intolerance to Other Anti—TNF Therapies</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-22</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses data from RHAPSODY [NCT00478660; AS], ReAct [NCT00650026; RA], and STEREO [NCT00235885; PsA] - 3 open-label trials that examined the effectiveness of adalimumab treatment in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriatic arthritis who had a history of anti-TNF therapy.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>